Anuh Pharma Limited · NSE:ANUHPHR
Anuh Pharma — Q2 FY2025 Earnings Presentation
33 slides from Anuh Pharma's earnings presentation, Nov 29, 2024
Slide 1: Cover letter to BSE for investor presentation
Date: 29th November, 2024 To, The Manager (Listing) BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001 Ref: Scrip Code No. 506260 Sub: Investor Presentation – Q2 FY2024-25 Dear Sir/Madam, With reference to the subject mentioned above and pursuant to Regulation 30 of SEBI (Li
Slide 2: Anuh Pharma Ltd. Investor Presentation FY2025
ANUH PHARMA LTD. Investor Presentation FY2025 (Nov‐24) BSE Scrip Code: 506260 Bloomberg Code: ANUH IN Reuters Code: ANUH.BO www.anuhpharma.com 1
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation may include certain “forward looking statements”, based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the Company does not guarantee realization of these statements. The Company also disclaims any
Slide 4: Table of content
Table of content 01 H1 FY 2025 & FY 2024 HIGHLIGHTS 02 COMPANY OVERVIEW 03 INFRASTRUCTURE 04 FUTURE OUTLOOK 05 CORPORATE SOCIAL RESPONSIBILITY ANUH PHARMA LTD.
Slide 5: H1 2025 & FY 2024 Highlights
01 H1 2025 & FY 2024 HIGHLIGHTS
Slide 6: Message from Joint MD
Message from Joint MD Dear Valued Share Holder, We are delighted to present to you the Investor presentation for 2nd quarter ended of FY 2025. We would like to share some key highlights that demonstrate our ongoing commitment to growth and value creation. Top Line: The company has clocked Revenue of
Slide 7: Message from Joint MD
Message from Joint MD Product Expansion: In addition to these metrics, we would like to highlight our market share growth in recently launched products like Acebrophylline, Vildagliptin, Moxifloxacin, Allopurinol, Amodiquine hcl,and Sulfadimethoxine. These indicators reflect our strong market positi
Slide 8: Financial performance highlights (last 5 years)
Financial performance highlights (last 5 years) Total Revenue (INR in Cr.) EBITDA (INR in Cr.) 659 537 87 492 443 55 52 57 312 27 19‐20 20‐21 21‐22 22‐23 23‐24 19‐20 20‐21 21‐22 22‐23 23‐24 PBT (INR in Cr.) PAT (INR in Cr.) 78 60 47 39 39 36 28 31 19 14 19‐20 20‐21 21‐22 22‐23 23‐24 7
Slide 9: Business mix revenue contribution
Business mix revenue contribution Revenue Split (Rs. In Cr.) Top 5 customers contribution 33% 302 310 32% 32% 32% 176 162 31% 139 135 30% Domestic Export Total H1 FY 25 H1 FY 24 H1 FY 25 H1 FY 24 Export Sales Domestic Sales Total Sales GEOGRAPHICAL EXPORT SALES H1 FY 25 GEOGRAPHICAL EXPORT SALES H1
Slide 10: Product mix revenue contribution
Product mix revenue contribution H1 FY 24 H1 FY 25 (INR in Cr.) 100 80 56 48 50 44 43 39 20 18 23 18 16 15 15 10 11 6 9
Slide 11: Track Record
Track Record EBITDA Margin % Net Profit Margin % 13.48 9.30 12.76 10.69 10.89 6.86 6.58 6.28 8.79 4.66 19‐20 20‐21 21‐22 22‐23 23‐24 19‐20 20‐21 21‐22 22‐23 23‐24 ROE (%) ROCE (%) 23 26.82 16 15 16 19.54 19.85 14 18.58 12.21 19‐20 20‐21 21‐22 22‐23 23‐24 19‐20 20‐21 21‐22 22‐23 23‐24 10
Slide 12: Track Record
Track Record Outflow of Dividend (INR in Cr.) Current ratio 2.20 17 1.98 1.91 1.70 13 10 1.37 9 8 19‐20 20‐21 21‐22 22‐23 23‐24 19‐20 20‐21 21‐22 22‐23 23‐24 Debt to Equity Net Working Capital (Days) 0.27 58 61 56 47 35 0.07 0.01 ‐ 0.01 19‐20 20‐21 21‐22 22‐23 23‐24 19‐20 20‐21 21‐22 22‐23 23‐24 11
Slide 13: H1 FY25 and FY24 Financial Performance
H1 FY 25 and FY 24 Financial Performance Rs. In Cr. 3 months 3 months Variance 6 months 6 months Variance Particulars ended ended (%) ended ended (%) 30/09/2024 30/06/2024 QoQ 30/09/2024 30/09/2023 YoY Operating Revenue 165.95 137.91 20.34 303.86 311.01 (2.30) Operating Profit 38.44 31.15 23.39 69.5
Slide 14: Company Overview
02 COMPANY OVERVIEW
Slide 15: Company Overview
Company Overview The Company derived ~47% of its revenues from exports in FY23‐24. The Company has strong marketing partnerships with 360 customers in over 59 countries including Europe, Mexico and South Africa. The expansion project with state of the art manufacturing facility targeted at regulated
Slide 16: Journey So Far…
Journey So Far… Year Achievements 1989 Started manufacturing Erythromycin salts with capacity of 150 MTPA , followed by doubling the capacity to 300 MTPA in 1995. 2002 Received WHO‐GMP for its facilities. 2006 Doubled the capacity by acquiring new plot of 1800 SQMT to expand the output capacity 600
Slide 17: Journey So Far…
Journey So Far… Year Achievements Received EU GMP for Erythromycin, Erythromycin ethyl succinate, Pyrazinamide, Pyrimethmine and Sulphadoxine from AEMPS 2019 Spain. 2019 Enhanced the capacity by acquiring new plot of 7800 SQMT to expand the output capacity by 600 MTPA. 2019 USFDA inspection passed s
Slide 18: Competitive Advantage
Competitive Advantage Market leadership: Erythromycin salts Competitive Advantage Pyrazinamide • Regulatory approvals • Environmental health and Safety Compliance (Audited an Sulfadoxine approved by Multinational companies). Ambroxol HCL • Well diversified sourcing with backward integration in key p
Slide 19: Key Management Personnel & Senior Management
Key Management Personnel & Senior Management VC VICE CHAIRMAN MR. BIPIN SHAH JMD JMD JOINT JOINT MANAGING MANAGING DIRECTOR DIRECTOR MR. RITESH SHAH MR. VIVEK SHAH VP CS & VP MARKETING CFO COMPLIANCE R&D QUALITY OPERATION QUALITY OFFICER MR. RAJU MR. DARSHAN Mr. Manan Vadhan DR. SANJAY MR. SANJAY MR
Slide 20: Key Management Personnel & Senior Management
Key Management Personnel & Senior Management Name Designation Profile Mr. Arun Todarwal Chairman Fellow member of the ICAI and having practice since 1981. He has handled various professional assignments in India and abroad including Audits, Taxation, International Taxation, Joint Ventures, Due Dilig
Slide 21: Latest Shareholding Pattern
Latest Shareholding Pattern Public 30.08 % Promoter & Promoter Group, 69.92 % Market capitalization INR 977 Cr. (As on 22nd November, 2024) Free float market capitalization INR 294 Cr. (As on 22nd November, 2024) 20
Slide 22: Infrastructure
03 INFRASTRUCTURE
Slide 23: State of Art manufacturing facility
State of Art manufacturing facility • Anuh Pharma has a EUGMP/ WHO Pre qualified approved manufacturing facility at Tarapur spread across 11,400 sq. meters with 8 API’s blocks and 1 intermediate block with total capacity of 1800 MTPA – this includes new expanded capacity. • With commissioning of Zer
Slide 24: Major Equipment Capabilities
Major Equipment Capabilities SNO. EQUIPMENT MOC CAPACITY QTY NOTES: 1 REACTOR WITH CONDENSER AND RECEIVER SS 316 650 L TO 10 KL 37 • The entire area is supplied with 3 Micron Filtered Forced Draft Ventilation. 2 REACTOR WITH CONDENSER AND RECEIVER GLR 500 L TO 10 KL 8 • The utilities are connected s
Slide 25: Major Equipment- Utility Capabilities
Major Equipment- Utility Capabilities SNO. EQUIPMENT QTY CAPACITY USE 1 BOILER 2 2000 KG/HR WITH PRESSURE OF 10 GENERATION OF STEAM KG/CM² 2 COMPRESSOR 4 700 CFM FOR AIR JET MILLING 3 WATER SYSTEM 2 3000 LITRES/HR FOR SUPPLY OF PURIFIED WATER 4 CHILLING PLANT 5 90TR, 95 TR & 270TR,220&297 TR FOR CHI
Slide 26: Other Facilitates
Other Facilitates The entire facility is equipped with latest Fire Fighting and Safety Measures. Zero Liquid Discharge Effluent Control system for treating 100% of Generated Pollution. 100% Power Backup via dedicated power line from Power Distributor to our premises. Adjoining office and a Training
Slide 27: Dedicated Research & Development Facility
Dedicated Research & Development Facility FACILITATE ACTIVITIES LAB SCALE REACTION THAT LEAD TO DEVELOP PROCESSES AND BATCHES TO VALIDATE CHARACTERIZATION AND PRODUCTS. RESEARCH PROFILING OF PRODUCTS. ANALYTICAL DEV CHEMICAL SYNTHESIS PILOT PLANT IN HOUSE R&D LAB APL NEW PRODUCTS & PROCESSES A dedic
Slide 28: Future Outlook
04 FUTURE OUTLOOK
Slide 29: Future Outlook – Growth Strategy
Future Outlook – Growth Strategy Marketing: • Increase Contribution from new Geographies especially in Japan, Vietnam and South Korea. • Continued focus on increasing market share in Corticosteroids, for which manufacturing capacity at L&L site is enhanced to 12 MTPA. • To tap opportunities with CEP
Slide 30: Future Outlook – Product under development
Future Outlook – Product under development Sr. No Product Name Therapeutic application 1) Ticagrelor Anti Platelet 2) Dapagliflozin Anti Diabetic 3) Empagliflozin Anti Diabetic 4) Bilastine HCl Anti‐Histamine 5) Pyronaridine Anti‐Malarial Tetraphosphate 6) Vonoprazon Anti‐Ulcerative Fumarate 29
Slide 31: Corporate Social Responsibility
05 CORPORATE SOCIAL RESPONSIBILITY
Slide 32: CSR …. Servicing Society for better tomorrow
CSR …. Servicing Society for better tomorrow • APL takes corporate sustainability and social responsibility as a voluntary commitment rather than an obligation. We engage in social activities encompassing education, healthcare, sanitation, vocational skill building, rural development & natural conse
Slide 33: Thank You
Thank You For specific queries please feel free to contact; Mr. Darshan Rampariya (CFO) darshan.r@anuhpharma.com